Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, Cancer, Pulmonary |
| Therapuetic Areas: | Oncology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2009 |
| End Date: | June 2012 |
An Open-Label Phase II Study of Zometa as Adjuvant Treatment of Malignant Pleural Effusion Due to Non-Small Cell Lung Cancer
The purpose of this study is to evaluate whether the addition of the bisphosphonate Zometa
(zoledronic acid) used along with standard regimens of chemotherapy, will help to control
the need for palliative intervention of malignant pleural effusions due to non-small cell
lung cancer.
Malignant pleural effusions are common in late stage non-small cell lung cancer and can lead
to significantly increased morbidity in this patient population. The majority of patients
are symptomatic due to their malignant effusions. The recurrence rates are thought to be
quite high overall and may approach 100% without any further treatment.Currently there is no
available non-invasive, medical means for controlling the effusions other than systemic
chemotherapy.Zoledronic acid has been shown in a mouse model of malignant pleural effusion
to decrease fluid accumulation and tumor dissemination while prolonging survival.
We found this trial at
1
site
Click here to add this to my saved trials
